Professor Helen McShane

Senior Research Fellow

Helen McShane has extensive experience in TB immunology and vaccinology. She is currently a Professor of Vaccinology at Oxford University, Wellcome Senior Clinical Research Fellow, Deputy Head of Department for Nuffield Department of Medicine and Honorary Consultant physician in HIV medicine.

Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997 She was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005, she was awarded a Wellcome Senior Clinical Research Fellowship; this Fellowship was renewed in 2010. Helen has led the TB vaccine research group at Oxford University for 15 years and notably headed the development of MVA85A; one of the most clinically advanced new TB vaccine candidates and the first to enter human efficacy testing.

She collaborates with several research groups in Africa in the conduct of clinical trials and current interests are in immunomonitoring in clinical trials, the development of human mycobacterial challenge models and aerosol delivery of vaccines.

Selected Publications

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O’Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatheril M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications. 2016 April 12. Article number: 11290. doi:10.1038/ncomms11290

Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; for the MVA85A 030 trial investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015 Feb 25. pii: S2213-2600(15)00037-5. [Epub ahead of print] PMID: 25726088

Satti I, Meyer J, Harris SA, Thomas ZR, Griffiths K, Antrobus RD, Rowland R, Ramon RL, Smith M, Sheehan S, Bettinson H, McShane H.  Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014. PMID:25151225

Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23; 381(9871):1021-8. PMID: 23391465

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AVSH. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycobacterial immunity in humans. Nature Medicine 2004. 10(11):1240-4. PMID: 15502839